Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Antidepressant Use by Youth with Minimal or Mild Depression: Evidence from 3 Health Systems.

Penfold RB, Stewart C, Simon GE, Shortreed SM, Johnson E, Rossom RC, Operskalski B, Beck A.

Pediatr Qual Saf. 2017;2(2). pii: e017. Epub 2017 Mar 22. No abstract available.

PMID:
28989993
2.

Treatment of anxiety disorders.

Bandelow B, Michaelis S, Wedekind D.

Dialogues Clin Neurosci. 2017 Jun;19(2):93-107.

3.

Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.

Shah D, Shah A, Tan X, Sambamoorthi U.

Drug Alcohol Depend. 2017 Aug 1;177:187-193. doi: 10.1016/j.drugalcdep.2017.03.021. Epub 2017 May 18.

PMID:
28605678
4.

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller HJ.

Int J Neuropsychopharmacol. 2017 Feb 1;20(2):121-179. doi: 10.1093/ijnp/pyw100.

5.

Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study.

Carracedo-Martínez E, Pia-Morandeira A.

SAGE Open Med. 2016 Aug 16;4:2050312116653054. doi: 10.1177/2050312116653054. eCollection 2016.

6.

Cognitive Behavioral Therapy in Primary Care for Youth Declining Antidepressants: A Randomized Trial.

Clarke G, DeBar LL, Pearson JA, Dickerson JF, Lynch FL, Gullion CM, Leo MC.

Pediatrics. 2016 May;137(5). pii: e20151851. doi: 10.1542/peds.2015-1851.

7.

Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.

Bushnell GA, Stürmer T, Swanson SA, White A, Azrael D, Pate V, Miller M.

Psychiatr Serv. 2016 Mar;67(3):302-9. doi: 10.1176/appi.ps.201500088. Epub 2015 Nov 16.

8.

The FDA And ABCs: Unintended Consequences Of Antidepressant Warnings On Human Capital.

Busch SH, Golberstein E, Meara E.

J Hum Resour. 2014 Summer;49(3):540-571.

9.

The statistics of suicide.

Gibbons RD.

Shanghai Arch Psychiatry. 2013 Apr;25(2):124-30. doi: 10.3969/j.issn.1002-0829.2013.02.011. No abstract available.

10.

Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.

Lu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold RB, Simon G, Ahmedani BK, Clarke G, Hunkeler EM, Waitzfelder B, Owen-Smith A, Raebel MA, Rossom R, Coleman KJ, Copeland LA, Soumerai SB.

BMJ. 2014 Jun 18;348:g3596. doi: 10.1136/bmj.g3596.

11.

Long-term trend in pediatric antidepressant use, 1983-2007: a population-based study.

Meng X, D'Arcy C, Tempier R.

Can J Psychiatry. 2014 Feb;59(2):89-97. Review.

12.

Anxiety, Depression, and Somatic Distress: Developing a Transdiagnostic Internalizing Toolbox for Pediatric Practice.

Weersing VR, Rozenman MS, Maher-Bridge M, Campo JV.

Cogn Behav Pract. 2012 Feb 1;19(1):68-82.

13.

Near infrared spectroscopy study of the frontopolar hemodynamic response and depressive mood in children with major depressive disorder: a pilot study.

Usami M, Iwadare Y, Kodaira M, Watanabe K, Saito K.

PLoS One. 2014 Jan 23;9(1):e86290. doi: 10.1371/journal.pone.0086290. eCollection 2014.

14.

National trends in psychotropic medication use in young children: 1994-2009.

Chirdkiatgumchai V, Xiao H, Fredstrom BK, Adams RE, Epstein JN, Shah SS, Brinkman WB, Kahn RS, Froehlich TE.

Pediatrics. 2013 Oct;132(4):615-23. doi: 10.1542/peds.2013-1546. Epub 2013 Sep 30.

15.

Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription.

Sparks JA, Duncan BL.

J Can Acad Child Adolesc Psychiatry. 2013 Aug;22(3):240-6.

16.

Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011.

Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR.

PLoS One. 2013 Jul 17;8(7):e68976. doi: 10.1371/journal.pone.0068976. Print 2013.

17.

A critical review of methods to evaluate the impact of FDA regulatory actions.

Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH.

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):986-94. doi: 10.1002/pds.3480. Epub 2013 Jul 12. Review.

18.

Author response.

Lam RW.

J Psychiatry Neurosci. 2013 Jul;38(4):E11-2. doi: 10.1503/jpn.130055. No abstract available.

19.

Depression and its associated factors in pediatric chronic kidney disease.

Kogon AJ, Vander Stoep A, Weiss NS, Smith J, Flynn JT, McCauley E.

Pediatr Nephrol. 2013 Sep;28(9):1855-61. doi: 10.1007/s00467-013-2497-5. Epub 2013 May 23.

20.

Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups.

DePetris AE, Cook BL.

Psychiatr Serv. 2013 May 1;64(5):466-71, 471.e1-4. doi: 10.1176/appi.ps.201200087.

Supplemental Content

Support Center